Lixte Biotechnology Holdings, Inc. LIXT
Set alert
At close · Jul 2
After hours · Jul 2, 4:00 PM ET
- YTD
- +83.46%
- 1 year
- +836.36%
- Open
- 7.81
- Prev close
- 7.21
- Mkt cap
- 4.70M
- Vol
- 615.06K
- Avg vol
- 580.55K
- EPS
- -1.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.00
- High
- 7.95
- Forward P/E
- 0.00
- Beta
- -0.17
- Short ratio
- 0.31
- Inst. own
- 9.64%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.86
- 200-d avg
- 2.27
- 1y target
- 0.00
Key statistics
- Market cap
- 4.70M
- Enterprise value
- 4.59M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.50
- EPS (TTM)
- -1.73
- Beta
- -0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.95M
- Total cash
- 2.60M
- Total debt
- 0
- Return on equity
- -163.33%
- Shares outstanding
- 2.25M
- Short % of float
- 20.44%
- 50-day average
- 1.86
- 200-day average
- 2.27
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.44 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.45 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.43 | — | — |
| Mar 19, 2024 | Dec 1, 2023 | 0.00 | -0.41 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.49 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -1.00 | — | — |
About Lixte Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lixte.com
News
- AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD
- LIXTE Biotechnology Changes Corporate Name To NOMAD Power Solutions, Ticker To NMAD, Effective July 2
- LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
- LIXTE Joins Russell Microcap Index
- LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
- The New Bottleneck Isn’t Computing Power — It’s Just Power
- LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on LIXT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERNARDS RENE | Director | Purchase | Oct 2, 2023 | 160,000 |
| VAN DER BAAN BASTIAAN JEROEN | Chief Executive Officer | Purchase | Oct 2, 2023 | 11,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HighTower Advisors, LLC | 4.42% | 99,432 | 207.81K | Sep 29, 2024 |
| FNY Investment Advisers, LLC | 3.18% | 71,638 | 149.72K | Sep 29, 2024 |
| Ethos Financial Group, LLC | 1.10% | 24,808 | 51.85K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.76% | 17,161 | 35.87K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.09% | 2,110 | 4.41K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 367 | 767 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.52% | 11,657 | 24.36K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.23% | 5,209 | 10.89K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 2,706 | 5.66K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.11% | 2,579 | 5.39K | Oct 30, 2024 |